Joseph Jemsek
Infectious Disease · Washington, DCNPI 1821075615
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 30.7% of the total. Reporting peaked in 2022 at $817 and has fallen 98.0% since, to $16 in 2025.
Across 126 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$708
- Pfizer$371
- Biohaven Pharmaceutical Holding Company Ltd.$222
- AbbVie$218
- Lilly USA, LLC$184
- Harmony Biosciences LLC$145
- plus $461 from 10 others
What the payments were for
- Food & beverage$2,310100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 54 | $708 |
| Pfizer | 16 | $371 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $222 |
| AbbVie | 8 | $218 |
| Lilly USA, LLC | 10 | $184 |
| Harmony Biosciences LLC | 5 | $145 |
| QOL Medical, LLC | 4 | $97 |
| Novartis | 4 | $93 |
| Romark Laboratories, LC | 3 | $77 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Eisai Inc. | 1 | $21 |
| Scynexis, Inc. | 1 | $21 |
| Bausch Health US, LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,310 in reported general payments places this provider in the 75th percentile of 74 infectious disease providers in District of Columbia.
See all infectious disease providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rifabutin | 23 | $7,511 |
| Atovaquone | 13 | $6,414 |
| Gabapentin | 71 | $3,016 |
| Fluconazole | 69 | $1,685 |
| CefuroximeCefuroxime Axetil | 29 | $1,200 |
| Azithromycin | 39 | $1,160 |
| Cefdinir | 24 | $1,059 |
| Hydroxyzine Hcl | 26 | $1,011 |
| Desmopressin Acetate | 13 | $935 |
| Lamotrigine | 49 | $886 |
| Minocycline Hcl | 56 | $781 |
| Hydrocortisone | 26 | $743 |
| Oxcarbazepine | 15 | $581 |
| Metronidazole | 59 | $475 |
| Trazodone Hcl | 34 | $349 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Washington
- Jesse GoodmanWashington$1.8M
- Theo HodgeWashington$1M
- Robert GasserWashington$922K
- Princy KumarWashington$270K
- Jose ChavezWashington$254K
- Linda NabhaWashington$60K
- Gebeyehu TeferiWashington$25K
- Jose BordonWashington$12K
- Rebecca KumarWashington$12K
- Jeffrey MurrayWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.